Dizal's ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026
In a recent study, ZEGFROVY® as a primary treatment option showed an impressive 81.3% objective response rate among individuals with advanced non-small cell lung cancer (NSCLC) possessing EGFR PACC or less common genetic mutations. This demonstrates the drug's notable efficacy in this specific patient population. The treatment also exhibited a favorable safety profile making it a promising option for these patients. The study was conducted by Dizal, a biopharmaceutical company based in Shanghai. This data was disclosed on March 27, 2026, and the company is listed on the Shanghai Stock Exchange under the symbol SSE:688192.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments